Picture by Joanna Kosinska via UnsplashLicencingSanofi inks up-to-$1.2bn autoimmune T-cell engager deal with Kali TherapeuticsSanofi is expanding its immunology toolbox: The French pharma pays up to US$1.2bn for worldwide exclusive rights to Kali Therapeutics’ next-generation tri-specific T-cell engager targeting B cell-mediated … more ➔
Unsplash+FinancingDutch biotech Laigo Bio bags €17m in oversubscribed seed roundMembrane protein degradation specialist Laigo Bio has completed the final close of its €17m (US$18.5m) seed financing. Funds will go towards the oncology and auto-immunity programmes based on the company’s … more ➔
adobe stock photos - Michael Derrer Fuchs SwitzerlandNovartis strikes another billion-dollar oncology deal with acquisition of an early PI3Kalpha oral therapyNovartis is pressing ahead with its aggressive expansion strategy in oncology, striking again: the Basel-based group is acquiring a novel PI3Kalpha inhibitor from Synnovation Therapeutics for up to USD … more ➔
adobe stock photos - Sundry Photography RocheSwiss Roche builds its own AI factory with NVIDIA – with Genentech in CaliforniaThe Basel-based pharmaceutical group Roche is pressing ahead with its digital strategy and setting new benchmarks for the industry. Together with NVIDIA, the company is building an “AI factory” that … more ➔
FundraisingMestag Therapeutics raises $40M and adds two senior biotech executives as lead cancer program nears the clinicUK biotech Mestag Therapeutics has raised $40 million and appointed veteran drug developers Lindsey Rolfe as chief medical officer and Pascal Merchiers as chief development officer, as the company prepares … more ➔
adobe stock photos - deemerwhaIntracellular targetingDelivering drugs into cells: Seed funding for German iDEL and its ‘wonder shuttle’The new Dortmund-based biotech iDEL Therapeutics has launched with a €9 million seed round to develop a new class of cancer therapies. The financing was led by BiomedVC, with participation from NRW.Venture, … more ➔
AITernary Therapeutics lands €4.1M seed round to push AI-designed molecular glues into inflammatory diseaseLondon-based Ternary Therapeutics has raised a €4.1 million seed round to expand its platform for designing molecular glue drugs, with Paris-based VC daphni leading the financing alongside Pace Ventures, … more ➔
AIOwkin spins out AI diagnostics startup Waiv with $33M financingFrench AI biotech Owkin has spun out its diagnostics division as a new company, Waiv, raising $33 million in financing led by OTB Ventures and Alpha Intelligence Capital to scale AI-powered precision … more ➔
Valanx BiotechAntibody drug conjugatesVienna’s VALANX secures €3 million to push preclinical ADC programme in breast cancerVALANX Biotech has raised €3 million in a Series A funding round to advance an antibody-drug conjugate (ADC) targeting LIV-1 for triple-negative breast cancer. The developments are currently still … more ➔
M&AEnodia strikes up to $127m deal for Kezar’s preclinical protein degradation assetsParis-based Enodia Therapeutics announced the acquisition of preclinical assets from San Francisco-based Kezar Life Sciences’ pipeline. Both companies are developers of small molecules that target … more ➔
Picture by Joanna Kosinska via Unsplash
Unsplash+
adobe stock photos - Michael Derrer Fuchs 
adobe stock photos - Sundry Photography 
adobe stock photos - deemerwha
Valanx Biotech
